A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit/hyperactivity disorder

Carlson, Gabrielle A.; Dunn, David W.; Kelsey, Douglas K.; Ruff, Dustin; Ball, Susan; Ahrbecker, Lisa; Allen, Albert J.

doi:10.1186/1753-2000-1-10

Cited by 39 publications

(51 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The rate of irritability exceeds that typically observed with either ATMX or OROS MPH alone (Swanson et al 2004;Wilens et al 2006;Newcorn et al 2008). The one prior study of combined ATMX and OROS MPH found no occurrences of irritability; however, only 9 children were exposed to combination treatment (Carlson et al 2007). …”

Section: Discussionmentioning

confidence: 99%

“…In their one small prior study of combined ATMX and OROS MPH, Carlson et al (2007) reported a 5-bpm increase in HR.…”

Section: Hammerness Et Almentioning

confidence: 99%

“…Conversely, there was no significant change in SBP. In a prior small and controlled study, Carlson et al (2007) reported a 2.1 mmHg mean increase in SBP and a 3 mmHg mean increase in DBP associated with OROS MPH in combination with ATMX.…”

Section: Hammerness Et Almentioning

confidence: 99%

“…In one prior report of combination ATMX and the extendedrelease stimulant OROS methylphenidate (MPH) in a small sample of children with ADHD (Carlson et al 2007), numerically fewer treatment emergent AEs were observed in the combined ATMX plus MPH group compared with ATMX monotherapy (ATMX= placebo). However, patients in the combined ATMX=MPH group did have a mean decrease in weight of 0.89 kg, as compared to a small increase in weight with ATMX monotherapy.…”

Section: Introductionmentioning

confidence: 99%

“…Given the proven efficacy, and variable mechanisms of action of stimulant and nonstimulant (atomoxetine [ATMX]) agents (Wilens 2006), combination treatment with these two classes of agents makes conceptual sense. However, to date, there is a lack of safety and tolerability data for this regimen in children; the literature is limited to case series or clinical reviews of the use of combination ATMX and stimulant therapy in children and adults (Brown 2004;Carlson et al 2007).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

An Open Study of Adjunct OROS-Methylphenidate in Children Who Are Atomoxetine Partial Responders: II. Tolerability and Pharmacokinetics

Hammerness

Georgiopoulos

Doyle

et al. 2009

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

Objective: The aim of this study was to evaluate the tolerability of adding OROS methylphenidate (MPH) to children who are partial responders to atomoxetine (ATMX) in the treatment of attention-deficit=hyperactivity disorder (ADHD). Methods: This was a two-phase, 7-week, open study in children aged 6-17 years. Phase 1 initiated ATMX for a minimum of 4 weeks. Phase 2 entered partial responders to ATMX and added OROS MPH to their regimen. Safety was assessed using blood pressure and heart rate measurements, electrocardiogram readings, AEs, laboratories, and ATMX levels. Results: Fifty subjects who were partial responders to ATMX received the combination therapy, with 41 subjects completing the entire protocol. As reported elsewhere , OROS MPH added to partial responders of ATMX was accompanied by a 40% reduction in the ADHD rating scale score and improvements in executive functioning. However, the combination of ATMX plus OROS MPH was associated with greater rates of insomnia, irritability, and loss of appetite compared to ATMX alone. A small significant increase in diastolic blood pressure was observed during adjunctive OROS MPH, with no clinically meaningful changes in electrocardiogram (ECG) parameters during the study. ATMX levels and liver function tests did not significantly change during the combination treatment. Conclusion: Adjunct OROS MPH in ATMX partial responders yielded an additive adverse effect burden in this short-term study. Further controlled research with larger samples of children is warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In their one small prior study of combined ATMX and OROS MPH, Carlson et al (2007) reported a 5-bpm increase in HR.…”

Section: Hammerness Et Almentioning

confidence: 99%

Section: Hammerness Et Almentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%